Table 1. Characterization of recombinant PALs.
| Candidate | Titers (g/L) | Specific Activity (Pre-PEGylation) | Specific Activity (Post-PEGylation) | Km (mM) | kcat (s-1) (per active site) | kcat/Km |
|---|---|---|---|---|---|---|
| rRtPAL(R91K) | 5–9 | 4.8 IU/mg | 1.6 IU/mg | 1.1 | 4 | 3.6 |
| rNpPAL* | 0.275 | 0.9 IU/mg | 0.3 IU/mg | 0.05 | 0.49 | 9.8 |
| rAvPALWT | 10–15 | 2.0 IU/mg | 1.6–2.0 IU/mg | 0.06 | 1.15 | 19.2 |
| rAvPAL(C503S/C565S) | 10–15 | 2.0 IU/mg | 1.6–2.0 IU/mg | 0.05 | 1.0 | 20 |
| rAvPAL(C503S/C565S)-PEG | 1.6–2.0 IU/mg | 0.05 | 1.2 | 24 |
*rNpPAL co-expressed with GroEL/ES to enhance expression